Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Biocon Limited ( (IN:BIOCON) ) just unveiled an update.
Biocon Limited announced that its subsidiary, Biocon Pharma Limited, has received approval from the US FDA for its ANDA for Everolimus Tablets, which are used in organ transplantation. This approval enhances Biocon’s portfolio of complex drug products, potentially strengthening its market position and offering new opportunities for growth.
More about Biocon Limited
Biocon Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of complex drug products. The company is known for its vertically integrated approach and serves markets with a focus on prescription medications.
YTD Price Performance: -17.25%
Average Trading Volume: 164,169
Current Market Cap: 366.4B INR
See more data about BIOCON stock on TipRanks’ Stock Analysis page.